<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33875855</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1759-5037</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature reviews. Endocrinology</Title><ISOAbbreviation>Nat Rev Endocrinol</ISOAbbreviation></Journal><ArticleTitle>Long COVID - metabolic risk factors and novel therapeutic management.</ArticleTitle><Pagination><StartPage>379</StartPage><EndPage>380</EndPage><MedlinePgn>379-380</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41574-021-00495-0</ELocationID><Abstract><AbstractText>Cardiometabolic conditions, including type 1 and type 2 diabetes mellitus, are associated with severe COVID-19 and long COVID. Interventions to target multiple risk factors, combined with use of novel glucose-lowering agents that improve metabolic function and the key processes that are impaired in COVID-19, should be the preferred therapeutic options for management of people with long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khunti</LastName><ForeName>Kamlesh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Leicester Diabetes Centre, University of Leicester, Leicester, UK. kk22@le.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Melanie J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Leicester Diabetes Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosiborod</LastName><ForeName>Mikhail N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Missouri-Kansas City, Kansas City, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nauck</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-5749-6954</Identifier><AffiliationInfo><Affiliation>Diabetes Center Bochum-Hattingen, St. Josef-Hospital, Ruhr-University, Bochum, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Endocrinol</MedlineTA><NlmUniqueID>101500078</NlmUniqueID><ISSNLinking>1759-5029</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000083202" MajorTopicYN="Y">Cardiometabolic Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>K.K. has acted as a consultant, speaker or received grants for investigator-initiated studies for AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp &amp; Dohme, Boehringer Ingelheim, Bayer, Berlin-Chemie AG / Menarini Group, Janssen and Napp. M.J.D. reported board membership and consultancy fees from Novo Nordisk, Sanofi-Aventis, Lilly, Merck, Sharp &amp; Dohme, Boehringer Ingelheim, AstraZeneca, Servier and Janssen. M.J.D. reported institutional grants from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim and Janssen. M.J.D. reported payment for lectures or speakers bureaus from Novo Nordisk, Sanofi-Aventis, Lilly, Merck, Sharp &amp; Dohme, Boehringer Ingelheim, AstraZeneca, Janssen, Mitsubishi Tanabe Pharma and Takeda Pharmaceuticals International. M.K. has received grants, honoraria and other research support from AstraZeneca, grants and honoraria from Boehringer Ingelheim, and honoraria from Sanofi, Amgen, Novo Nordisk, Merck (Diabetes), Eisai, Janssen, Bayer, GlaxoSmithKline, Glytec, Intarcia, Novartis, Applied Therapeutics, Amarin and Eli Lilly. M.K. is CI for the DARE Trial. M.A.N. has been member on advisory boards or has consulted with AstraZeneca, Boehringer Ingelheim, Eli Lilly &amp; Co., Menarini/Berlin Chemie, Merck, Sharp &amp; Dohme, NovoNordisk and Servier/Versatis. M.A.N. has received grant support from Afimmune, Eli Lilly &amp; Co., Menarini/Berlin-Chemie and Merck, Sharp &amp; Dohme. M.A.N. has also served on the speakers&#x2019; bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly &amp; Co., Menarini/Berlin Chemie, Merck, Sharp &amp; Dohme, NovoNordisk and Sun Pharma.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33875855</ArticleId><ArticleId IdType="pmc">PMC8054121</ArticleId><ArticleId IdType="doi">10.1038/s41574-021-00495-0</ArticleId><ArticleId IdType="pii">10.1038/s41574-021-00495-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singh AK, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. Diabetes Obes. Metab. 2020;22:1915&#x2013;1924. doi: 10.1111/dom.14124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14124</ArticleId><ArticleId IdType="pmc">PMC7361304</ArticleId><ArticleId IdType="pubmed">32573903</ArticleId></ArticleIdList></Reference><Reference><Citation>Barron E, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8:813&#x2013;822. doi: 10.1016/S2213-8587(20)30272-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(20)30272-2</ArticleId><ArticleId IdType="pmc">PMC7426088</ArticleId><ArticleId IdType="pubmed">32798472</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A, et al. Multi-organ impairment in low-risk individuals with long COVID. BMJ Open. 2021;11:e048391. doi: 10.1136/bmjopen-2020-046311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-046311</ArticleId><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Boyton RJ. Decoding the unknowns in long covid. BMJ. 2021;372:n132. doi: 10.1136/bmj.n132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n132</ArticleId><ArticleId IdType="pubmed">33541867</ArticleId></ArticleIdList></Reference><Reference><Citation>Potere N, et al. Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Crit. Care. 2020;24:389. doi: 10.1186/s13054-020-03022-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03022-1</ArticleId><ArticleId IdType="pmc">PMC7330272</ArticleId><ArticleId IdType="pubmed">32616077</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat. Rev. Endocrinol. 2020;17:11&#x2013;30. doi: 10.1038/s41574-020-00435-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-020-00435-4</ArticleId><ArticleId IdType="pmc">PMC7664589</ArticleId><ArticleId IdType="pubmed">33188364</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidu S, et al. The impact of obesity on severe disease and mortality in people with SARS-CoV-2: A systematic review and meta-analysis. Endocrinol. Diabetes Metab. 2020;4:e00176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460942</ArticleId><ArticleId IdType="pubmed">32904932</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K, Kosiborod M, Ray KK. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia? Diabetes Obes. Metab. 2018;20:1337&#x2013;1341. doi: 10.1111/dom.13243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13243</ArticleId><ArticleId IdType="pubmed">29405543</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelniker TA, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139:2022&#x2013;2031. doi: 10.1161/CIRCULATIONAHA.118.038868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.038868</ArticleId><ArticleId IdType="pubmed">30786725</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K. Type 2 diabetes mellitus in 2020: SGLT2 inhibitors in people with and without T2DM. Nat. Rev. Endocrinol. 2021;17:75&#x2013;76. doi: 10.1038/s41574-020-00453-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-020-00453-2</ArticleId><ArticleId IdType="pubmed">33293703</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>